Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-12-01
2011-10-11
Wehbe, Anne Marie S (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S003700, C424S085200
Reexamination Certificate
active
08034790
ABSTRACT:
Methods of suppressing or preventing an infection of a subject by a pathogen that involve administering to the subject a composition that includes a therapeutically effective amount of an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and a pharmaceutically acceptable preparation suitable for delivery to the subject, wherein the MDA-7 suppresses or prevents the infection, are disclosed. Also disclosed are methods of suppressing or preventing a viral infection of a cell, including obtaining an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and contacting the cell with the MDA-7 polypeptide or the nucleic acid encoding the MDA-7 polypeptide, wherein the MDA-7 suppresses or prevents infection of the cell.
REFERENCES:
patent: 4682195 (1987-07-01), Yilmaz
patent: 4683202 (1987-07-01), Mullis
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5179122 (1993-01-01), Greene et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5543158 (1996-08-01), Gref et al.
patent: 5633016 (1997-05-01), Johnson
patent: 5641515 (1997-06-01), Ramtoola
patent: 5643761 (1997-07-01), Fisher et al.
patent: 5645897 (1997-07-01), Andra
patent: 5705629 (1998-01-01), Bhongle
patent: 5710137 (1998-01-01), Fisher
patent: 5739169 (1998-04-01), Ocain et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5798339 (1998-08-01), Brandes
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5824311 (1998-10-01), Greene et al.
patent: 5824348 (1998-10-01), Fujiu et al.
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 5846225 (1998-12-01), Rosengart et al.
patent: 5846233 (1998-12-01), Lilley et al.
patent: 5846945 (1998-12-01), McCormick
patent: 6069134 (2000-05-01), Roth et al.
patent: 6132980 (2000-10-01), Wang et al.
patent: 6168791 (2001-01-01), Larsen et al.
patent: 6177074 (2001-01-01), Glue et al.
patent: 6204022 (2001-03-01), Johnson et al.
patent: 6207145 (2001-03-01), Tovey
patent: 6207648 (2001-03-01), Waxman et al.
patent: 6250469 (2001-06-01), Kline
patent: 6326466 (2001-12-01), Bottaro et al.
patent: 6331525 (2001-12-01), Chiou et al.
patent: 6342379 (2002-01-01), Tsien et al.
patent: 6348352 (2002-02-01), Shepard et al.
patent: 6350589 (2002-02-01), Morris et al.
patent: 6355622 (2002-03-01), Fisher
patent: 6372218 (2002-04-01), Cummins
patent: 6379701 (2002-04-01), Tracy et al.
patent: 6407218 (2002-06-01), Tamarkin et al.
patent: 6855686 (2005-02-01), Fischer
patent: 2002/0091098 (2002-07-01), Fisher
patent: 2002/0183271 (2002-12-01), Chada et al.
patent: 2003/0066095 (2003-04-01), Baubet et al.
patent: 2003/0082140 (2003-05-01), Fisher
patent: 2003/0147966 (2003-08-01), Franzen et al.
patent: 2003/0223938 (2003-12-01), Nagy et al.
patent: 2004/0009939 (2004-01-01), Chada et al.
patent: 2004/0191223 (2004-09-01), Fisher
patent: 2005/0101770 (2005-05-01), Presta
patent: 2005/0143336 (2005-06-01), Ramesh et al.
patent: 2005/0191277 (2005-09-01), Fisher
patent: 2005/0250127 (2005-11-01), Fisher et al.
patent: 2006/0110376 (2006-05-01), Fisher et al.
patent: 2006/0134801 (2006-06-01), Chada et al.
patent: 2006/0292157 (2006-12-01), Fisher et al.
patent: 0 266 032 (1988-05-01), None
patent: WO 95/11986 (1995-05-01), None
patent: WO 95/28948 (1995-11-01), None
patent: WO 98/07408 (1998-02-01), None
patent: WO 98/16655 (1998-04-01), None
patent: WO 98/28425 (1998-07-01), None
patent: WO 98/35554 (1998-08-01), None
patent: WO 00/05356 (2000-02-01), None
patent: WO 00/26368 (2000-05-01), None
patent: WO 00/61626 (2000-10-01), None
patent: WO 00/71096 (2000-11-01), None
patent: WO 01/05437 (2001-02-01), None
patent: WO 01/60365 (2001-08-01), None
patent: WO 02/04511 (2002-01-01), None
patent: WO 02/45737 (2002-06-01), None
patent: WO 03/075952 (2003-09-01), None
patent: WO 03/087308 (2003-10-01), None
Wilson et al. Adv. Drug Deliv. Rev. 46:205-209; 2001.
Thomas et al. Nature Rev./Genet. 4: 346-358; 2003.
Caudell et al. (2002) J. Immunol., vol. 168, 6041-6046.
Uchikawa et al. (2000) Infection and Immunity, vol. 68(11), pp. 6233-6299.
Taylor et al. (2000) Infection and Immunity, vol. 68(4), 1815-1819.
La Flamme et al. (2001) Infection and Immunity, vol. 69(12), pp. 7445-7452.
Nishimura et al. (2004) J. Parasitol., vol. 90(4)740-745.
Albert et al., “Dendritic cell matuation is required for the cross-tolerization of CD8+ T cells,”Nat Immunol, 2(11):1010-1017, 1998.
Anderson, “Human gene therapy,”Nature, 392:25-30, 1998.
Angiolillo et al., “A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12,”Ann. NY Acad Sci., 795:158-167, 1996.
Austin-Ward and Villaseca, “Gene therapy and its applications,” abstract only,Rev. Med. Chil., 126:838-845, 1998.
Balachandran et al., “Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling,”EMBO J.,17(23):6888-6902, 1998.
Beretta et al., “Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation,”EMBO J, 15:658-664, 1996.
Beretta et al., “Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection,”J. Virol, 70:8993-8996, 1996.
Blumberg et al., “Inyrtlrukin 20: discovery, receptor identification, and role in epidermal function,”Cell104:9-19, 2001.
Bonavida et al., “Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics,”Int J Oncol, 15:793-802, 1999.
Boucher et al., “Status of gene therapy for cystic fibrosis lung disease ,”J. Clin. Invest., 103:441-445, 1999.
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science, 247(4948):1306-10, 1990.
Bukowski et al., “Signal transducton abnormalities in T lymphyocytes from patients with advanced renal carcinoma: Clinical relevance and effects of cytokine therapy,”Clin. Cancer Res., 4(10):2337-2347, 1998.
Cao et al., “Adenoviral transfer of mda-7 leads to BAX up-regulation and in mesothelioma cells, and is abrogated by over-expression of BCL-XL,”Molecular Medicine, 8(12):869-876, 2002.
Caudell et al., “The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24,”J. Immunol, 168(12):6041-6046, 2002.
Chattergoon et al., “Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-medicated apoptosis,”Nat Biotechnol, 18(9):974-979, 2000.
Chen and Tan, “Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin,”Ocongene, 17:173-178, 1998.
Chinnaiyan et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy,”Proc Nat'l Acad Sci USA. 97:1754-1759, 2000.
Christodoulides et al., “Immunization with recombinant class 1 outer-membrane protein fromNeisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response againstmeningococci,”Microbiology, 144:3027-3037, 1998.
Cross et al., “A p53-dependent mouse spindle checkpoint,”Science, 267:1353-1356, 1995.
Crystal, “Transfer of genes to humans: early lessons and obstacles to success,”Science, 270:404-409, 1995.
Cuddihy et al., “Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53,”Mol. Cell. Biol., 19(4):2475-2484, 1999.
Cunningham et al., “Clinical and local biological effects of an intratumoral injection ofmda-7(IL24; INGN 241) in patients with advanced carcinoma: a phase I study,”Molecular Therapy, 11(1):149-159, 2005. (Written in 2003 with Applicant).
Dagon et al., &#x
Fulbright & Jaworski L.L.P.
Introgen Therapeutics
Wehbe Anne Marie S
LandOfFree
Use of MDA-7 to inhibit pathogenic infectious organisms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of MDA-7 to inhibit pathogenic infectious organisms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of MDA-7 to inhibit pathogenic infectious organisms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284057